LEO Pharma has brought a 21-poster scientific programme to the 2026 Fall Clinical Dermatology Conference, highlighting research involving delgocitinib cream for chronic hand eczema, spesolimab for generalized pustular psoriasis and tralokinumab for atopic dermatitis. Announced on October 8, 2026, the programme includes additional safety analyses from the Phase 3 DELTA TEEN trial, long-term biologic treatment research, real-world patient outcomes and epidemiological investigations spanning four dermatological conditions.
The conference, held from October 8 to 11 in Las Vegas, places particular emphasis on Anzupgo (delgocitinib) cream as LEO Pharma pursues regulatory authorisation for adolescents aged 12 to 17 years with moderate to severe chronic hand eczema. The United States Food and Drug Administration accepted the company’s supplemental New Drug Application in April 2026, while European regulators issued a positive scientific opinion in September recommending an extension of the existing adult indication. Neither development constitutes final regulatory approval for adolescent treatment, making additional safety evidence especially relevant.
The wider scientific programme also supports LEO Pharma’s commercial strategy around established dermatology medicines, including Spevigo (spesolimab-sbzo) for generalized pustular psoriasis and Adbry (tralokinumab-ldrm) for atopic dermatitis. Importantly, the 21 presentations are not equivalent to 21 new clinical trials or 21 independently positive treatment results. They include original research, previously presented analyses, observational studies, patient surveys and epidemiological investigations, each offering different levels of clinical and commercial evidence.
How strong are the DELTA TEEN Phase 3 results supporting Anzupgo’s adolescent approval application?
The strongest regulatory evidence behind LEO Pharma’s chronic hand eczema programme comes from DELTA TEEN, a randomized, double-blind, vehicle-controlled Phase 3 study involving 98 adolescents aged 12 to 17 years. Participants received either delgocitinib 2% cream or a matching vehicle twice daily over 16 weeks, with 74 assigned to active treatment and 24 to the control group. The trial evaluated adolescents with moderate to severe chronic hand eczema for whom topical corticosteroid treatment was inadequate or inappropriate.
The primary endpoint was treatment success on the Investigator’s Global Assessment for Chronic Hand Eczema at Week 16, defined as clear or almost clear skin together with an improvement of at least two severity grades from baseline. Results published in The Lancet Child & Adolescent Health showed that 47 of 74 patients receiving delgocitinib, or approximately 64%, achieved treatment success, compared with seven of 24 patients, or 29%, receiving the vehicle. The analysis demonstrated superiority on the prespecified primary endpoint, providing the efficacy foundation for the company’s regulatory submissions.
The study also generated information about adverse events during the treatment period. Adverse events occurred in 50% of delgocitinib-treated participants and 33% of vehicle recipients, with all events reported in the active treatment group classified as mild or moderate. No serious adverse events were reported in either group during the 16-week randomized treatment period, although the relatively small trial population limits its ability to identify uncommon risks.
The Fall Clinical Dermatology programme includes a further analysis of systemic exposure and safety, alongside research examining baseline disease burden and treatment history. Systemic exposure is particularly relevant because delgocitinib inhibits multiple Janus kinase pathways, and regulators must consider whether repeated topical application creates clinically meaningful drug exposure beyond the treated skin. The conference announcement did not disclose quantitative results from the additional pharmacokinetic and safety poster, so conclusions about systemic exposure should remain tied to the complete dataset rather than assumptions based on topical administration.
Why could the FDA and European regulatory decisions be important for Anzupgo’s growth?
Anzupgo received United States Food and Drug Administration approval in July 2025 for moderate to severe chronic hand eczema in adults who have had an inadequate response to topical corticosteroids or for whom those treatments are not advisable. Its mechanism involves topical inhibition of Janus kinase signalling pathways associated with skin inflammation. The medicine represents a nonsteroidal treatment option within its approved indication, but its availability for adults does not establish approval for younger patients.
The regulatory position has advanced considerably during 2026. The FDA accepted the supplemental application covering adolescents in April, while the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on September 18 recommending the corresponding expansion in the European Union. The European Commission must still issue a final authorisation decision, and the FDA review remains separate from the European process.
The potential adolescent indication addresses a patient population for whom disease-specific treatment options remain limited. Chronic hand eczema can interfere with school activities, sports, social interaction and everyday functioning, particularly when itching, painful fissures or visible skin lesions persist despite existing treatment. However, commercial adoption following any authorisation would still depend on prescribing information, physician acceptance, reimbursement and the medicine’s safety considerations.
The United States prescribing information includes warnings concerning infections, non-melanoma skin cancers, vaccination and potential risks associated with Janus kinase inhibition. The label also states that it is not known whether Anzupgo is associated with certain serious adverse effects observed with other Janus kinase inhibitors, including cardiovascular events, thrombosis and malignancy. An expanded age indication would not eliminate those considerations, making the adolescent safety evidence important to both regulatory assessment and clinical adoption.
What do the chronic hand eczema real-world studies reveal about treatment burden and unmet needs?
Beyond the pivotal trial, the conference includes research examining how chronic hand eczema affects working adults and how patients are treated in routine United States clinical practice. Several presentations address topical corticosteroid utilisation, productivity impairment, quality of life and difficulties performing everyday activities. Additional studies examine disease burden across different skin tones and describe the design of a prospective observational registry for patients in the United States and Canada.
This research addresses a commercially and clinically relevant limitation of traditional treatment evaluation. Physician-assessed improvements in redness, scaling and disease severity are important, but patients may place equal emphasis on pain while washing their hands, difficulty using workplace equipment, sleep disruption and the ability to maintain employment. Measuring these outcomes can help establish whether treatment benefits extend into activities that influence healthcare utilisation and quality of life.
Earlier findings presented by LEO Pharma at the European Academy of Dermatology and Venereology Congress in October provide related real-world context. In an interim analysis of the German REACHED observational study, 28.6% of adults receiving delgocitinib were assessed as clear or almost clear after eight weeks, compared with none at baseline. Mean Hand Eczema Severity Index scores declined from 62.4 to 30.8, while patient-reported quality-of-life measures also improved.
Those observational findings are not equivalent to a randomized comparison against another active medicine or an untreated control group. Changes in clinical practice, background treatment, patient selection and follow-up can influence outcomes outside controlled trials. Nevertheless, combining randomized efficacy data with observational treatment experience may help payers and dermatologists understand how the medicine performs after commercial introduction.
The new United States research could be particularly useful in evaluating differences between clinical trial populations and patients receiving treatment in everyday settings. Disease severity, occupational exposure, previous corticosteroid use and healthcare access may affect treatment patterns. The conference announcement identifies these research areas but does not provide numerical results for every poster, preventing a definitive assessment of their findings from the programme announcement alone.
What does the Spevigo research reveal about long-term generalized pustular psoriasis management?
LEO Pharma’s generalized pustular psoriasis programme includes five presentations examining clinical characteristics, treatment patterns, long-term therapy and disease prevalence. Three presentations focus on original observational research, while two previously presented analyses revisit longer-term findings from the EFFISAYIL development programme. The distinction is important because the conference does not represent the first disclosure of every long-term treatment outcome.
Spevigo, developed by Boehringer Ingelheim and subsequently licensed to LEO Pharma, is a monoclonal antibody targeting the interleukin-36 receptor. This pathway plays an important role in generalized pustular psoriasis, a rare inflammatory disorder characterised by episodes of widespread sterile pustules and potentially serious systemic complications. Unlike ordinary plaque psoriasis, generalized pustular psoriasis can involve acute inflammatory flares that require urgent medical attention.
In the United States, Spevigo is approved for generalized pustular psoriasis in adults and pediatric patients aged 12 years and older who weigh at least 40 kilograms. Intravenous administration is used for treatment of flares, while the subcutaneous formulation provides a treatment approach for ongoing disease control. These distinct administration strategies create a need for evidence covering both sustained treatment and the management of breakthrough flares.
The conference programme includes research from the five-year open-label EFFISAYIL ON extension examining intravenous treatment or retreatment of flares among patients receiving subcutaneous spesolimab. Another presentation considers efficacy and safety over periods of at least three years within the EFFISAYIL programme. Such follow-up can provide information about continued disease management, although open-label extension studies require careful interpretation because patients remaining in long-term research may differ from those who discontinue treatment.
Additional observational research examines treatment patterns and clinical characteristics among United States patients with generalized pustular psoriasis. These studies could help establish how often patients require acute interventions, the extent of prior treatment exposure and the burden associated with recurrent disease activity. The commercial relevance lies in understanding how an approved targeted medicine fits into a rare-disease pathway that may require both maintenance treatment and rapid management of unpredictable flares.
How could the TRACE and ADHAND findings influence real-world use of tralokinumab?
The atopic dermatitis programme includes six presentations involving tralokinumab, marketed as Adbry in the United States and Adtralza in several other markets. The monoclonal antibody targets interleukin-13, a cytokine involved in type 2 inflammatory signalling associated with atopic dermatitis. Its United States indication covers patients aged 12 years and older with moderate to severe atopic dermatitis that is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
The non-interventional TRACE study is a major component of the conference programme. The research examines real-world effectiveness and safety outcomes over 12 months, including patterns of treatment response in adults receiving tralokinumab during routine care. Observational evidence is relevant because patients outside randomized clinical trials can have different comorbidities, previous treatment histories and patterns of medication use.
LEO Pharma’s October 1 disclosure from the European dermatology congress provides additional detail about the same research programme. Among 91 participants whose atopic dermatitis initially affected three high-burden anatomical regions, 48 were assessed at Month 12, and 79.2% of those remaining reported fewer affected regions. However, the decline in the number of participants available for the final assessment means that those percentages should not be interpreted as outcomes for the entire original subgroup.
The ADHAND Phase 3b trial provides a different type of evidence because it used a randomized, placebo-controlled design to study tralokinumab in adults with atopic dermatitis and moderate to severe hand involvement. At Week 16, 76.6% of patients receiving tralokinumab achieved at least a four-point improvement in the Dermatology Life Quality Index, compared with 44.7% receiving placebo. These previously reported findings support improvements in patient-reported quality of life within the studied population, although they do not establish superiority over other approved biologic therapies.
For clinicians, evidence involving difficult anatomical locations can be useful when assessing treatment options for patients whose disease affects everyday functioning disproportionately. Hand involvement can interfere with work and personal care, while lesions affecting the face, neck or other sensitive regions may create substantial psychosocial burden. Nevertheless, differences in trial populations and assessment methods make direct comparisons between tralokinumab and competing systemic treatments unreliable without appropriately designed comparative studies.
Why does the TRAPEDS 1 research matter for younger children with atopic dermatitis?
Another presentation examines tralokinumab-associated changes in skin lipid composition and natural moisturising factor biomarkers in children with moderate to severe atopic dermatitis. The research is linked to the Phase 2 TRAPEDS 1 programme, which evaluates pharmacokinetics and long-term safety in children aged six to 11 years. This age group is younger than the population covered by the medicine’s current United States atopic dermatitis indication.
LEO Pharma reported earlier in July 2026 that the pharmacokinetic findings were consistent with expectations and that no new safety signals had been identified during the disclosed long-term treatment experience. Those company-reported results contribute to the paediatric development programme, but the latest biomarker presentation addresses a more specific biological question. Changes in skin lipids or natural moisturising factors may indicate effects on barrier-related processes without independently proving improved clinical outcomes.
Atopic dermatitis involves interactions between immune inflammation and skin barrier dysfunction, making both processes relevant to therapeutic development. A treatment that reduces inflammatory signalling could potentially influence barrier-associated biomarkers, but confirming patient benefit requires appropriate clinical assessments of disease severity, symptoms and quality of life. The poster’s biomarker findings should therefore be regarded as supportive scientific evidence rather than proof of efficacy in an unapproved age group.
Any extension of tralokinumab treatment to younger children would require the applicable regulatory review and authorisation. The Phase 2 programme provides information relevant to that process, but the conference presentation does not represent an approval, an accepted marketing application or a confirmed commercial launch for patients younger than 12 years.
Why is LEO Pharma studying pyoderma gangrenosum prevalence without announcing a new treatment result?
The conference includes one presentation examining United States incidence and prevalence estimates for pyoderma gangrenosum using a large administrative claims database. Unlike the delgocitinib, spesolimab and tralokinumab presentations, this research is primarily epidemiological rather than a report of treatment efficacy. Its value lies in improving understanding of a rare inflammatory disease that can be difficult to diagnose and distinguish from other causes of skin ulceration.
Pyoderma gangrenosum is associated with painful, potentially progressive skin ulcers and can occur alongside other inflammatory or systemic disorders. Diagnosis can be challenging because there is no single universally definitive laboratory test, and clinical presentation may overlap with infection, vascular disease and other conditions. This uncertainty complicates epidemiological measurement, particularly when studies rely on administrative coding rather than independently confirmed diagnoses.
Large claims datasets can help estimate healthcare utilisation and identify patterns across broad populations, but they also have limitations involving coding accuracy, access to care and incomplete clinical information. Prevalence estimates derived from such databases should be interpreted according to the case definitions used. The conference announcement does not provide the numerical incidence or prevalence findings, making it inappropriate to assign a new United States disease estimate based solely on the presentation title.
LEO Pharma’s wider pipeline includes investigation of spesolimab in pyoderma gangrenosum, but the latest epidemiological poster is not evidence that the medicine works for that condition. Improved disease characterisation can inform trial design, recruitment planning and assessments of unmet need, while clinical efficacy and safety require separate controlled investigation.
How does the 21-poster dermatology programme support LEO Pharma’s commercial growth strategy?
The research programme arrives during a period of investment and portfolio expansion for the Denmark-headquartered pharmaceutical company. In the first half of 2026, LEO Pharma reported revenue of DKK 7.257 billion, representing a 7% increase in reported terms and 10% growth at constant exchange rates. Its strategic dermatology brands, Anzupgo, Spevigo and Adtralza/Adbry, collectively recorded 50% revenue growth at constant exchange rates.
The financial performance demonstrates increasing commercial importance for the medicines highlighted in the conference programme. However, aggregate brand growth cannot be attributed specifically to the October presentations, and the company has not disclosed a revenue forecast associated with the studies. Clinical evidence development can support prescribing confidence, regulatory submissions and payer discussions, but each commercial outcome depends on additional implementation and market factors.
The company reported adjusted earnings before interest, taxes, depreciation and amortisation of DKK 1.247 billion during the first half, compared with DKK 1.456 billion a year earlier. Its adjusted margin declined from 21% to 17%, reflecting greater expenditure on commercial activities, development and innovation despite improved gross margin performance. LEO Pharma also revised its full-year adjusted margin outlook to 14% to 16% in August, while increasing its constant-currency revenue growth forecast to 9% to 11%.
These financial trends show why evidence generation and disciplined portfolio investment are connected. Supporting several established products while pursuing label extensions and new indications requires additional research expenditure, regulatory resources and commercial infrastructure. LEO Pharma is privately held, with the LEO Foundation as majority shareholder and Nordic Capital as a co-owner, so its performance is better assessed through operating results and business development rather than a publicly traded share price.
The conference programme also reflects a broader strategy of building evidence beyond initial product approvals. Long-term observational studies, patient-reported outcomes and epidemiological research can influence how medicines are understood after launch, particularly in chronic diseases involving substantial quality-of-life burdens. Such evidence is most useful when its limitations are clearly recognised and when it adds clinically relevant information beyond the original registration trials.
What are the next important regulatory and clinical milestones for LEO Pharma’s dermatology portfolio?
The most immediate regulatory developments concern delgocitinib’s proposed adolescent indication. The European Commission’s decision following the positive Committee for Medicinal Products for Human Use opinion and the FDA’s assessment of the supplemental application will determine whether Anzupgo can be marketed for the specified younger population in those jurisdictions. Neither regulator’s decision should be inferred from positive conference presentations alone.
For the approved medicines, the next tests are predominantly commercial and evidence-related. Spevigo’s long-term development programme must continue clarifying disease control, breakthrough flare management and safety during extended treatment. Tralokinumab research will need to demonstrate how controlled-trial efficacy translates into sustained real-world outcomes, while studies in younger children remain subject to separate development and regulatory requirements.
The additional chronic hand eczema observational research may also influence future treatment evaluation by documenting work impairment, quality-of-life changes and variation in clinical practice. However, observational findings cannot automatically establish that a medicine reduces healthcare costs or improves productivity without appropriate comparative evidence. Their strongest contribution will be to identify where existing treatments fall short and which outcomes deserve greater attention in future research.
LEO Pharma’s 21 presentations illustrate a maturing dermatology strategy built around regulatory expansion, established commercial products and continued investigation of difficult inflammatory skin diseases. The central near-term opportunity is the proposed extension of Anzupgo into adolescent chronic hand eczema, supported by randomized Phase 3 evidence but still awaiting final regulatory decisions. Longer-term progress will depend on whether the company’s growing body of clinical and real-world research translates into sustainable prescribing, stronger patient outcomes and commercially productive investment across its dermatology portfolio.
